Acute Pancreatitis Market Research Report Information By Cause (Gallstones, Alcohol and Others), By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP) and Others), By Diagnosis (Imaging Tests and Laboratory Tests), By End-User (Hospitals, Clinics and Others), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

Acute Pancreatitis Market Overview:

Acute Pancreatitis Market Size was valued at USD 5.88 Billion in 2023. The Global Acute Pancreatitis industry is projected to grow from USD 6.29 Billion in 2024 to USD 18.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.70% during the forecast period (2024 - 2032). The major market driver fueling the expansion is the increased prevalence of gastrointestinal issues.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Orphan Drug Designation Has Been Granted to Olezarsen, an Investigational Medicine Developed by Ionis Pharmaceuticals, Inc. for the Treatment of Familial Chylomicronemia Syndrome (FCS), a Rare Genetic Disease That Causes Very High Triglyceride Levels in the Body Followed by Recurrent Acute Pancreatitis (AP), by FDA. When a drug is used to diagnose, prevent or treat diseases that affect less than 200000 people at the time of use, it is considered an orphan drug. Among these enzymes, FCS specifically affects the fats’ disintegration process, and fasting triglyceride levels can increase up to 10-100 times more than is common. The inflammation may cause hospitalization due to severe pancreatitis AP that can be fatal. People with FCS are prone to developing conditions like AP that inflame the pancreas, thus causing hospitalization, which might be lethal. Harsher instances hurt critical organs like the lungs, heart, kidney, liver, and pancreas.

UCB announced today that ZILBRYSQ® (zilucoplan) has been approved by the FDA as a new treatment for adult patients suffering from generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. An option of daily subcutaneous regimen2 provides zilucoplan, which is an important C5 inhibitot2 with peptide targeting. Besides others, it is anticholinesterase among adults with AChR antibody-positive gMG.Its specific mechanisms inhibiting complement-mediated damage at NMJ act as C5 complement inhibitor2, allowing zilucoplan. While advantages of self-administration do exist when patients receive therapy from home without necessarily going back to the hospital, among other things, this saves time when commutated between different locations and consequently allows patients to have more control over their lives.

Zydus Lifesciences Limited (hereinafter referred to as ‘Zydus’, including its subsidiaries/affiliates) announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for ZITUVIO™ (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg. Glycemic levels in type-2 diabetes mellitus patients can be managed with ZITUVIO alongside dieting and exercising. The approval of ZITUVIO™ is based on research, development, regulatory, and manufacturing work performed by Zydus teams. Nitrosamine testing results and potential genotoxic impurities were within acceptable limits as per current USFDA standards. Nitrosamines content in ZITUVIO™ Sitagliptin-containing products meets the standards set by the current USFDA guidelines regarding Nitrosamines.

Acute Pancreatitis Market Trends

• Increase in the occurrence of acute pancreatitis to propel market growth

According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 275,000 Americans are hospitalized for acute pancreatitis yearly (NIDDK). When the pancreas swells up and becomes irritated, pancreatitis results (swollen). It is not a widespread illness. The most common reasons are gallstones or binge drinking. The illness may grow gradually over time or manifest suddenly, causing great injury. Treatment for pancreatitis may include intravenous (IV) fluids, painkillers, and other medicines. The increase in the occurrence of acute pancreatitis on a global scale will be a key factor in the market's increased growth rate. Gallstones and heavy drinking, especially among younger people, are the main causes of acute pancreatitis. Gallstones are the most frequent cause of AP, accounting for 28 to 38 percent of cases, and alcohol consumption is the second-most common cause, accounting for 19 to 41 percent of cases, according to an article published in the World Journal of Clinical Cases- Evaluation and management of acute pancreatitis in 2019. The likelihood of developing acute pancreatitis increases as the number of people with gallstones rises. Thus, this factor is driving the market CAGR.

Furthermore, globally, chronic comorbidities are becoming more common, and there is an increasing curiosity about how these comorbidities affect those with acute pancreatitis. In the early stages of acute pancreatitis, for instance, it has been discovered that gastrointestinal symptoms are linked to pre-existing metabolic syndrome, obesity, diabetes mellitus, and metabolic syndrome, according to a research paper published in BioMed Hub in November 2021. A PLOS One paper from June 2021 claims that obesity is also a big public health issue in France because it increases the likelihood of developing chronic conditions, including diabetes, hypertension, and other conditions with severe psychological and social repercussions. As a result, the increasing prevalence of obesity raises people's chance of getting pancreatitis due to overeating habits, which is expected to drive the segment's rise over the forecast period. The studied market is therefore anticipated to expand throughout the forecast period due to variables like the rising prevalence of obesity and the growing utilization of IV therapy.

However, the market will grow due to an increase in the elderly population and government measures to raise awareness. Along with this, shifting consumer lifestyles and expanding government-welcoming measures will accelerate market expansion. A rise in the quantity of R&D activities is another factor driving the market's expansion. Thus, it is anticipated that this aspect will accelerate acute pancreatitis market revenue globally.

Acute Pancreatitis Market Segment Insights:

Acute Pancreatitis Cause Insights

The Acute Pancreatitis Market segmentation, based on cause, includes gallstones, alcohol and others. The gallstones segment held the majority share in 2022 in the Acute Pancreatitis Market data. Globally, the prevalence of acute pancreatitis is rising along with the frequency of gallstones. About 40% of cases of acute pancreatitis are brought on by gallstones. Gallstones affect about 20 million people in the US. Each year, about 300,000 cholecystectomies are performed on these patients.

Acute Pancreatitis Treatment Insights

The Acute Pancreatitis Market segmentation, based on treatment, includes intravenous fluid, nutritional support, analgesics, endoscopic retrograde cholangiopancreatography (ERCP) and others. The intravenous fluid segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032 due to variables including the increased prevalence of acute pancreatitis, gallstones, and obesity in the population, as well as the risk factors that go along with them. Dehydration and severe fluid loss are associated with acute pancreatitis, which can be fatal and may result in the patient dying. The body is kept hydrated through intravenous fluid delivery, ensuring appropriate blood flow to all other organs.

Acute Pancreatitis Diagnosis Insights

The Acute Pancreatitis Market data, based on diagnosis, includes imaging tests and laboratory tests. The laboratory tests segment dominated the acute pancreatitis market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Amylase and lipase are crucial pancreatic enzymes diagnosed with laboratory tests. The following could cause one's blood to spill. Other blood tests can also be used to check for gallbladder blockage or damage.

Figure 2: Acute Pancreatitis Market, by Diagnosis, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Acute Pancreatitis End-User Insights

The global acute pancreatitis industry, based on end-user, includes hospitals, clinics and others. The hospitals segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The fact that hospitals are always well-stocked with all services available under one roof encourages patients with acute pancreatitis to go there for care. Another reason driving up hospital visits is the growing penetration of linked gadgets and equipment.

Acute Pancreatitis Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America acute pancreatitis market accounted for USD 2.5 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The prevalence of acute pancreatitis, obesity, and gallstone instances is rising. These conditions and the presence of a well-established healthcare infrastructure and high healthcare spending are all driving the market's expansion.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: ACUTE PANCREATITIS MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Asia Pacific acute pancreatitis market accounts for the second-largest market share. The risk of having pancreatic inflammation has increased due to the population's rising incidence of obesity due to their changing lifestyles, which is anticipated to drive market expansion. Acute pancreatitis medication and device-based therapies are expected to be in high demand, driving market expansion thanks to the region's expanding research and development efforts. Moreover, China acute pancreatitis market held the largest market share, and the India acute pancreatitis market was the fastest growing market in the region.

Europe acute pancreatitis Market is expected to grow at the fastest CAGR from 2024 to 2032. This is because the demand for particular treatments is increasing, and rising healthcare costs will further accelerate the market's growth rate in this area. The presence of important players and increased use of newer technologies will also accelerate the market's growth rate in this area. Further, the UK acute pancreatitis market held the largest market share, and the Germany acute pancreatitis market was the fastest growing market in the region.

Acute Pancreatitis Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the acute pancreatitis market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the acute pancreatitis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global acute pancreatitis industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, acute pancreatitis industry has provided medicine with some of the most significant benefits. The acute pancreatitis market major player such as SCM Lifescience, General Electric Company, CalciMedica, B. Braun Melsungen AG, Samsung Bioepis, Medtronic, Boston Scientific Corporation, Baxter International Inc., Fresenius Kabi USA, and GNT Pharma Co.

CalciMedica, a biopharmaceutical company in the clinical stage for the treatment of inflammatory illnesses like COVID-19 pneumonia and acute pancreatitis, are developing inhibitors of CRAC channels. Calcium, a crucial messenger chemical, must be transported into different types of cells through CRAC channels. CalciMedica has created a portfolio of wholly-owned CRAC channel inhibitors and unique assays to maximize chemical leads. In December 2022, auxora is the subject of Phase II clinical dose-ranging study by CalciMedica, Inc. in patients with acute pancreatitis and systemic inflammatory response syndrome.

The corporate headquarters of the American healthcare giant Baxter International Inc. is located in Deerfield, Illinois. The company's main areas of concentration include chronic and urgent medical issues, including kidney illness. Sales for the company's two segments, BioScience and Medical Products, totaled $10.6 billion in 2017. Recombinant and blood plasma proteins, plasma-based therapies, products for regenerative medicine, and vaccines are all produced by Baxter's BioScience division to treat hemophilia and other bleeding disorders, immunological deficiencies, and other chronic and acute blood-related illnesses.

Key Companies in the acute pancreatitis market includes

• CalciMedica


• SCM Lifescience


• Samsung Bioepis


• GNT Pharma Co.


• Baxter International Inc.


• Braun Melsungen AG


• General Electric Company


• Medtronic


• Boston Scientific Corporation


• Fresenius Kabi USA

Acute Pancreatitis Industry Developments

March 2022: Nafamostat and citrate anticoagulation (RCA), two distinct dialysis circuit anticoagulants, were compared in pediatric patients receiving continuous renal replacement treatment by AcelRx Pharmaceuticals, Inc. (CRRT). A serine protease inhibitor called nafamostat is used to treat acute pancreatitis.

January 2021: Olinvyk (oliceridine), an opioid-based medication, was introduced by Trevena, Inc. for treating acute pain. FDA authorized Olinvyk (oliceridine) in August 2020. Oliceridine, a Schedule II-restricted opioid-like drug with a high potential for abuse, is a component of OLINVYK.

Acute Pancreatitis Market Segmentation

Acute Pancreatitis Cause Outlook (USD Billion, 2024-2032)

• Gallstones


• Alcohol


• Others

Acute Pancreatitis Treatment Outlook (USD Billion,2023-2032)

• Intravenous fluid


• Nutritional support


• Analgesics


• Endoscopic Retrograde Cholangiopancreatography (ERCP)


• Others

Acute Pancreatitis Diagnosis Outlook (USD Billion, 2023-2032)

• Imaging Tests


• Laboratory Tests

Acute Pancreatitis End-user Outlook (USD Billion, 2023-2032)

• Hospitals


• Clinics


• Others

Acute Pancreatitis Regional Outlook (USD Billion, 2023-2032)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America